Market capitalization | $115.66m |
Enterprise Value | $97.31m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 12.97 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-45.48m |
Free Cash Flow (TTM) Free Cash Flow | $-35.07m |
Cash position | $18.35m |
As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.
3 Analysts have issued a Angion Biomedica Corp forecast:
3 Analysts have issued a Angion Biomedica Corp forecast:
Mar '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -44 -44 |
19%
19%
|
EBIT (Operating Income) EBIT | -45 -45 |
21%
21%
|
Net Profit | -51 -51 |
31%
31%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Angion Biomedica Corp. operates as a biopharmaceutical company. It focuses on the discovery and development of novel therapeutic agents to address acute organ injuries and fibrotic diseases. Its product pipeline includes ANG-3777, ANG-3070, ROCK2 Inhibitor and CYP11B2 Inhibitors. The company was founded by Itzhak D. Goldberg on April 06, 1998 and is headquartered in Uniondale, NY.
Head office | United States |
CEO | Robert Connelly |
Employees | 32 |
Founded | 2011 |
Website | elicio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.